Insight Molecular Diagnostics (IMDX) Net Cash Flow (2015 - 2026)

Insight Molecular Diagnostics has reported Net Cash Flow for 12 years, with the latest figure at $16.4 million in Q1 2026.

• Quarterly Net Cash Flow fell 26.62% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 112.8% YoY) and the FY2025 annual result came in at $2.7 million, up 450.13% from the prior year.
• Net Cash Flow rose to $16.4 million in Q1 2026 per IMDX's latest filing, from -$7.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $24.4 million in Q2 2022 and troughed at -$15.2 million in Q1 2022.
• A 5-year average of -$458588.2 and a median of -$4.4 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 304.27% in 2022, then soared 681.53% in 2025.
• Over 5 years, Net Cash Flow stood at -$10.5 million in 2022, then surged by 58.76% to -$4.4 million in 2023, then surged by 221.26% to $5.3 million in 2024, then plunged by 237.91% to -$7.3 million in 2025, then jumped by 326.03% to $16.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $16.4 million, -$7.3 million, and -$5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.